Kadimastem (XTAE:KDST) Short-Term Debt : ₪4.18 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Kadimastem Short-Term Debt?

Kadimastem's Short-Term Debt for the quarter that ended in Dec. 2023 was ₪4.18 Mil.

Kadimastem's quarterly Short-Term Debt declined from Dec. 2022 (₪4.17 Mil) to Jun. 2023 (₪3.97 Mil) but then increased from Jun. 2023 (₪3.97 Mil) to Dec. 2023 (₪4.18 Mil).

Kadimastem's annual Short-Term Debt declined from Dec. 2021 (₪4.22 Mil) to Dec. 2022 (₪4.17 Mil) but then increased from Dec. 2022 (₪4.17 Mil) to Dec. 2023 (₪4.18 Mil).

Kadimastem Short-Term Debt Historical Data

The historical data trend for Kadimastem's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kadimastem Short-Term Debt Chart

Kadimastem Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

5.52

10.53

4.22

4.17

4.18

Kadimastem Semi-Annual Data
	Dec13	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Short-Term Debt	Get a 7-Day Free Trial														4.22	4.03	4.17	3.97	4.18

Kadimastem Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Kadimastem Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Kadimastem's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Kadimastem (XTAE:KDST) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kadimastem Ltd (XTAE:KDST) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

KMSTF:USA

Address

Pinchas Sapir 7, Weizmann Science Park, Nes-Ziona, ISR

Website

http://www.kadimastem.com

Kadimastem Ltd is a biopharmaceutical company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS and Diabetes. It is developing revolutionary regenerative therapies based on stem cells.

Kadimastem (XTAE:KDST) Headlines

No Headlines